Tags

Type your tag names separated by a space and hit enter

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Nature. 2020 10; 586(7830):583-588.Nat

Abstract

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF

Authors+Show Affiliations

Mercado NB
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Zahn R
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Wegmann F
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Loos C
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Massachusetts Institute of Technology, Cambridge, MA, USA.
Chandrashekar A
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Yu J
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Liu J
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Peter L
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
McMahan K
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Tostanoski LH
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
He X
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Martinez DR
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rutten L
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Bos R
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
van Manen D
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Vellinga J
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Custers J
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Langedijk JP
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Kwaks T
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Bakkers MJG
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Zuijdgeest D
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Rosendahl Huber SK
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Atyeo C
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA.
Fischinger S
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA.
Burke JS
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Feldman J
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA.
Hauser BM
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA.
Caradonna TM
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA.
Bondzie EA
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Dagotto G
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Harvard Medical School, Boston, MA, USA.
Gebre MS
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Harvard Medical School, Boston, MA, USA.
Hoffman E
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jacob-Dolan C
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Harvard Medical School, Boston, MA, USA.
Kirilova M
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Li Z
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Lin Z
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Mahrokhian SH
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Maxfield LF
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nampanya F
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nityanandam R
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nkolola JP
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Patel S
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ventura JD
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Verrington K
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Wan H
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pessaint L
Bioqual, Rockville, MD, USA.
Van Ry A
Bioqual, Rockville, MD, USA.
Blade K
Bioqual, Rockville, MD, USA.
Strasbaugh A
Bioqual, Rockville, MD, USA.
Cabus M
Bioqual, Rockville, MD, USA.
Brown R
Bioqual, Rockville, MD, USA.
Cook A
Bioqual, Rockville, MD, USA.
Zouantchangadou S
Bioqual, Rockville, MD, USA.
Teow E
Bioqual, Rockville, MD, USA.
Andersen H
Bioqual, Rockville, MD, USA.
Lewis MG
Bioqual, Rockville, MD, USA.
Cai Y
Children's Hospital, Boston, MA, USA.
Chen B
Children's Hospital, Boston, MA, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.
Schmidt AG
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.
Reeves RK
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Baric RS
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lauffenburger DA
Massachusetts Institute of Technology, Cambridge, MA, USA.
Alter G
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.
Stoffels P
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Mammen M
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Van Hoof J
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Schuitemaker H
Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
Barouch DH
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. dbarouch@bidmc.harvard.edu. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. dbarouch@bidmc.harvard.edu. Harvard Medical School, Boston, MA, USA. dbarouch@bidmc.harvard.edu. Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA. dbarouch@bidmc.harvard.edu.

MeSH

AnimalsBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsDisease Models, AnimalFemaleImmunity, CellularImmunity, HumoralMacaca mulattaMalePandemicsPneumonia, ViralSARS-CoV-2VaccinationViral LoadViral Vaccines

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32731257

Clinical Trial Links

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

Citation

Mercado, Noe B., et al. "Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques." Nature, vol. 586, no. 7830, 2020, pp. 583-588.
Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583-588.
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., He, X., Martinez, D. R., Rutten, L., Bos, R., van Manen, D., Vellinga, J., Custers, J., Langedijk, J. P., Kwaks, T., ... Barouch, D. H. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 586(7830), 583-588. https://doi.org/10.1038/s41586-020-2607-z
Mercado NB, et al. Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques. Nature. 2020;586(7830):583-588. PubMed PMID: 32731257.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. AU - Mercado,Noe B, AU - Zahn,Roland, AU - Wegmann,Frank, AU - Loos,Carolin, AU - Chandrashekar,Abishek, AU - Yu,Jingyou, AU - Liu,Jinyan, AU - Peter,Lauren, AU - McMahan,Katherine, AU - Tostanoski,Lisa H, AU - He,Xuan, AU - Martinez,David R, AU - Rutten,Lucy, AU - Bos,Rinke, AU - van Manen,Danielle, AU - Vellinga,Jort, AU - Custers,Jerome, AU - Langedijk,Johannes P, AU - Kwaks,Ted, AU - Bakkers,Mark J G, AU - Zuijdgeest,David, AU - Rosendahl Huber,Sietske K, AU - Atyeo,Caroline, AU - Fischinger,Stephanie, AU - Burke,John S, AU - Feldman,Jared, AU - Hauser,Blake M, AU - Caradonna,Timothy M, AU - Bondzie,Esther A, AU - Dagotto,Gabriel, AU - Gebre,Makda S, AU - Hoffman,Emily, AU - Jacob-Dolan,Catherine, AU - Kirilova,Marinela, AU - Li,Zhenfeng, AU - Lin,Zijin, AU - Mahrokhian,Shant H, AU - Maxfield,Lori F, AU - Nampanya,Felix, AU - Nityanandam,Ramya, AU - Nkolola,Joseph P, AU - Patel,Shivani, AU - Ventura,John D, AU - Verrington,Kaylee, AU - Wan,Huahua, AU - Pessaint,Laurent, AU - Van Ry,Alex, AU - Blade,Kelvin, AU - Strasbaugh,Amanda, AU - Cabus,Mehtap, AU - Brown,Renita, AU - Cook,Anthony, AU - Zouantchangadou,Serge, AU - Teow,Elyse, AU - Andersen,Hanne, AU - Lewis,Mark G, AU - Cai,Yongfei, AU - Chen,Bing, AU - Schmidt,Aaron G, AU - Reeves,R Keith, AU - Baric,Ralph S, AU - Lauffenburger,Douglas A, AU - Alter,Galit, AU - Stoffels,Paul, AU - Mammen,Mathai, AU - Van Hoof,Johan, AU - Schuitemaker,Hanneke, AU - Barouch,Dan H, Y1 - 2020/07/30/ PY - 2020/06/20/received PY - 2020/07/24/accepted PY - 2020/7/31/pubmed PY - 2020/10/30/medline PY - 2020/7/31/entrez SP - 583 EP - 588 JF - Nature JO - Nature VL - 586 IS - 7830 N2 - A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/32731257/Single_shot_Ad26_vaccine_protects_against_SARS_CoV_2_in_rhesus_macaques_ L2 - https://doi.org/10.1038/s41586-020-2607-z DB - PRIME DP - Unbound Medicine ER -